Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.87 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.87 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.87 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.87 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.87 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.87 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.87 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.87 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.87 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.87 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.87 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | CASP3 | P42574 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.69 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27516050 | 1.00 | TDP1 (1.00) | TDP1L3MBTL1MAPTLMNAHDAC1 | |
| SCHEMBL8519287 | 1.00 | TDP1 (1.00) | TDP1L3MBTL1MAPTLMNAHDAC1 | |
| SCHEMBL7068671 | 0.97 | TDP1 (0.95) | TDP1L3MBTL1MAPTLMNAHDAC1 | |
| SCHEMBL3383102 | 0.93 | HDAC1 (1.00) | TDP1L3MBTL1MAPTLMNAHDAC1 | |
| SCHEMBL7824358 | 0.93 | HDAC1 (1.00) | TDP1L3MBTL1MAPTLMNAHDAC1 | |
| SCHEMBL9356269 | 0.93 | HDAC1 (1.00) | TDP1L3MBTL1MAPTLMNAHDAC1 | |
| SCHEMBL3378075 | 0.93 | HDAC1 (1.00) | TDP1L3MBTL1MAPTLMNAHDAC1 | |
| SCHEMBL9663087 | 0.93 | HDAC1 (1.00) | TDP1L3MBTL1MAPTLMNAHDAC1 | |
| SCHEMBL9352420 | 0.93 | HDAC1 (1.00) | TDP1L3MBTL1MAPTLMNAHDAC1 | |
| SCHEMBL3381106 | 0.93 | HDAC1 (1.00) | TDP1L3MBTL1MAPTLMNAHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10751330-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-25 | — | — | US | claimed |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-05-14 | — | — | US | claimed |
| US-10092550-B2 | Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof | IONS PHARMACEUTICAL S.À R.L. (LU) | 2018-10-09 | — | — | US | claimed |
| US-20170042865-A1 | THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-02-16 | — | — | US | claimed |
| US-20250255853-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2025-08-14 | — | — | US | disclosed |
| US-20240390294-A1 | INHIBITION OF COVID-19 VIRUS BY MULTIPLE-COMPONENT FORMULATIONS | ANKH LIFE SCIENCES LIMITED (IE) | 2024-11-28 | — | — | US | disclosed |
| US-20240285592-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2024-08-29 | — | — | US | disclosed |
| US-12053440-B2 | Inhibition of COVID-19 virus by formulations containing curcumin, harmine, and isovanillin | ANKH LIFE SCIENCES LIMITED (IE) | 2024-08-06 | — | — | US | disclosed |
| WO-2022140561-A1 | INHIBITION OF COVID-19 VIRUS BY MULTIPLE-COMPONENT FORMULATIONS | ANKH LIFE SCIENCES LIMITED (IE) | 2022-06-30 | — | — | WO | disclosed |
| US-20220193007-A1 | INHIBITION OF COVID-19 VIRUS BY MULTIPLE-COMPONENT FORMULATIONS | ANKH LIFE SCIENCES LIMITED (IE) | 2022-06-23 | — | — | US | disclosed |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2022-05-19 | — | — | US | disclosed |
| US-11266634-B2 | Methods for treating melanoma with human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2022-03-08 | — | — | US | disclosed |
| WO-1996022077-A1 | ARYL KETONES FOR COLOURING KERATIN-CONTAINING FIBRES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1996-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11266634-B2 | Methods for treating melanoma with human therapeutic agents | HNMT, INMT, TYR | TDP1 1245/4885L3MBTL1 1180/4885MAPT 1266/4885 |
| US-20220193007-A1 | INHIBITION OF COVID-19 VIRUS BY MULTIPLE-COMPONENT FORMULATIONS | IDO2, IDO1, MAVS | TDP1 3300/4885L3MBTL1 1857/4885MAPT 485/4885 |
| US-10751330-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | TDP1 1171/4885L3MBTL1 916/4885MAPT 497/4885 |
| US-20240285592-A1 | HUMAN THERAPEUTIC AGENTS | INMT, NLN, MYC | TDP1 975/4885L3MBTL1 764/4885MAPT 143/4885 |
| US-20170042865-A1 | THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, CPT1A | TDP1 989/4885L3MBTL1 1959/4885MAPT 212/4885 |
| US-10092550-B2 | Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof | INMT, HNMT, CPT1A | TDP1 989/4885L3MBTL1 1959/4885MAPT 212/4885 |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | TDP1 1171/4885L3MBTL1 916/4885MAPT 497/4885 |
| US-12053440-B2 | Inhibition of COVID-19 virus by formulations containing curcumin, harmine, and isovanillin | MAVS, IDO2, IDO1 | TDP1 2682/4885L3MBTL1 1648/4885MAPT 302/4885 |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | TDP1 1171/4885L3MBTL1 916/4885MAPT 497/4885 |
| US-20250255853-A1 | HUMAN THERAPEUTIC AGENTS | HASPIN, TIPARP, SHARPIN | TDP1 1647/4885L3MBTL1 745/4885MAPT 1131/4885 |
| US-20240390294-A1 | INHIBITION OF COVID-19 VIRUS BY MULTIPLE-COMPONENT FORMULATIONS | MAVS, IDO2, IDO1 | TDP1 3140/4885L3MBTL1 1744/4885MAPT 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.